Are CGRP and PACAP involved in the pathophysiology of peripheral neuropathic pain? - Archive ouverte HAL
Article Dans Une Revue Revue Neurologique Année : 2023

Are CGRP and PACAP involved in the pathophysiology of peripheral neuropathic pain?

Xavier Moisset

Résumé

Background: In relapsing-remitting multiple sclerosis (RRMS), early identification of suboptimal responders can prevent disability progression. Objective: We aimed to develop and validate a dynamic score to guide the early decision to switch from first- to second-line therapy. Methods: Using time-dependent propensity scores (PS) from a French cohort of 12,823 patients with RRMS, we constructed one training and two validation PS-matched cohorts to compare the switched patients to second-line treatment and the maintained patients. We used a frailty Cox model for predicting individual hazard ratios (iHRs). Results: From the validation PS-matched cohort of 348 independent patients with iHR ⩽ 0.69, we reported the 5-year relapse-free survival at 0.14 (95% confidence interval (CI) 0.09–0.22) for the waiting group and 0.40 (95% CI 0.32–0.51) for the switched group. From the validation PS-matched cohort of 518 independent patients with iHR > 0.69, these values were 0.37 (95% CI 0.30–0.46) and 0.44 (95% CI 0.37–0.52), respectively. Conclusions: By using the proposed dynamic score, we estimated that at least one-third of patients could benefit from an earlier switch to prevent relapse.

Dates et versions

hal-04721446 , version 1 (04-10-2024)

Identifiants

Citer

Xavier Moisset. Are CGRP and PACAP involved in the pathophysiology of peripheral neuropathic pain?. Revue Neurologique, 2023, 179 (3), pp.123-124. ⟨10.1016/j.neurol.2022.11.001⟩. ⟨hal-04721446⟩

Collections

PRES_CLERMONT ND
0 Consultations
0 Téléchargements

Altmetric

Partager

More